Author:
Tempero M.A.,Berlin J.,Ducreux M.,Haller D.,Harper P.,Khayat D.,Schmoll H.-J.,Sobrero A.,Van Cutsem E.
Reference46 articles.
1. American Cancer Society. Cancer Facts and Figures 2009. Atlanta, GA: American Cancer Society http://www.cancer.org/downloads/STT/500809web.pdf (4 May 2010, date last accessed)
2. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world;Kamangar;J Clin Oncol,2006
3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997
4. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group;Moore;J Clin Oncol,2007
5. Phase III trial of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group;Poplin;J Clin Oncol,2009
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献